Suppr超能文献

脆弱双核阿米巴感染的研究进展:该生物体在胃肠道疾病诊断中应被考虑的若干原因。

A review of Dientamoeba fragilis carriage in humans: several reasons why this organism should be considered in the diagnosis of gastrointestinal illness.

机构信息

Division of Microbiology, SydPath, St. Vincent's Hospital, Darlinghurst, Australia.

出版信息

Gut Microbes. 2011 Jan-Feb;2(1):3-12. doi: 10.4161/gmic.2.1.14755.

Abstract

Dientamoeba fragilis is a protozoan that inhabits the human gut. It is approximately 100 years since Dientamoeba's discovery and first description when it was described as a rare and harmless commensal. Since then it has struggled to gain recognition as a pathogen despite the evidence supporting its pathogenicity. Dientamoeba remains neglected, probably due to the misconceptions that it is uncommon and non-pathogenic. Usually, carriage of Dientamoeba is associated with symptoms such as abdominal pain and diarrhea. Moreover, antimicrobial therapy followed by resolution of symptoms coincides with the eradication of Dientamoeba. This manuscript reviews the scientific literature relating to Dientamoeba's prevalence and pathogenicity. While much of the evidence supporting its pathogenicity is only circumstantial, it is apparent that most researchers agree that Dientamoeba is pathogenic. Therefore, in symptomatic patients who harbor Dientamoeba and no other pathogen, Dientamoeba should be considered as the etiological agent and treated as such.

摘要

脆弱双核阿米巴是一种寄生于人体肠道的原生动物。自 100 年前首次发现并描述为一种罕见且无害的共生体以来,尽管有证据支持其致病性,但脆弱双核阿米巴一直难以被认为是一种病原体。脆弱双核阿米巴仍然被忽视,可能是因为人们误解它不常见且无致病性。通常,携带脆弱双核阿米巴与腹痛和腹泻等症状有关。此外,抗微生物治疗后症状缓解与脆弱双核阿米巴的消除相一致。本文综述了与脆弱双核阿米巴的流行率和致病性相关的科学文献。虽然支持其致病性的大部分证据只是间接证据,但很明显,大多数研究人员都认为脆弱双核阿米巴是一种病原体。因此,在没有其他病原体而仅携带脆弱双核阿米巴且有症状的患者中,应将脆弱双核阿米巴视为病因并进行相应治疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验